Print Page | Close Page

 
 

Lupin

Address: C/4 Laxmi Towers, Bandra Kurla Complex, Bandra (E), Mumbai, 400 051
 
Country: India
 
Sectors: Generic Formulations, Proprietary Research & Manufacture
 
Telephone: +91 22 6640 2222
 
Fax: +91 22 6640 2130
 
Website: https://www.lupin.com/LMS/
 
- - -
 

About Us

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company both in terms of market capitalization (30th June 2018, Bloomberg) and revenues (31st March 2018, Bloomberg LTM) globally. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT June 2018); 3rd largest Indian pharmaceutical company by global revenues (31st March 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2018). For the financial year ended 31st March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively.

 
- - -
 

Sectors

  • Generic Formulations
 
  • Proprietary Research & Manufacture
 
- - -
 

Categories

  • Generic Formulations
  • Finished Dosage
  • Small Molecules
  • Large Molecules
  • Active Pharmaceutical Ingredients
 
  • Biosimilars
  • Peptides
  • Bioprocess Development
  • High Potency API's
  • Cannabinoids
 
- - -
 

Certifications

  • GMP-United Kingdom-MHRA-Inspected
 

A PHP Error was encountered

Severity: Notice

Message: Undefined property: stdClass::$company_licence_detail_in

Filename: profile/print_profile.php

Line Number: 302

Backtrace:

File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 302
Function: _error_handler

File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view

File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once

A PHP Error was encountered

Severity: Notice

Message: Undefined property: stdClass::$company_licence_detail_out

Filename: profile/print_profile.php

Line Number: 303

Backtrace:

File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 303
Function: _error_handler

File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view

File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once

A PHP Error was encountered

Severity: Notice

Message: Undefined property: stdClass::$company_licence_detail_distributor

Filename: profile/print_profile.php

Line Number: 304

Backtrace:

File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 304
Function: _error_handler

File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view

File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once

A PHP Error was encountered

Severity: Notice

Message: Undefined property: stdClass::$company_licence_detail_researcher

Filename: profile/print_profile.php

Line Number: 305

Backtrace:

File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 305
Function: _error_handler

File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view

File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once

A PHP Error was encountered

Severity: Notice

Message: Undefined property: stdClass::$company_licence_detail_description

Filename: profile/print_profile.php

Line Number: 306

Backtrace:

File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 306
Function: _error_handler

File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view

File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once

 
- - -
 

News

 
15th December 2025
 

Lupin Manufacturing Solutions and PolyPeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain

 

Mumbai, Baar, December 12, 2025: Lupin Manufacturing Solutions (LMS), a subsidiary of global pharma major Lupin Limited (Lupin), today announced a long-term strategic alliance with PolyPeptide Group AG (PolyPeptide) (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients. This collaboration aims to enhance supply chain resilience, improve operational efficiency, and accelerate readiness for the rapidly expanding global peptides market. It also advances next-generation peptide therapeutics, including those for metabolics, supporting the long-term strategic growth of both organizations.

 
-
 
 
19th December 2018
 

Lupin receives US FDA approval for Clobazam Tablets, 10 mg and 20 mg

 

Mumbai, Baltimore, December 17, 2018: Pharma major Lupin announced that it has received approval for its Clobazam Tablets, 10 mg and 20 mg from the United States Food and Drug Administration (FDA) to market a generic version of Lundbeck Pharmaceuticals, LLC's Onfi Tablets, 10 mg and 20 mg.

 
-
 
 
05th September 2018
 

Lupin’s Tarapur API Manufacturing Facility Inspected by US FDA

 
Mumbai, September 4, 2018: Pharma major Lupin announced today the completion of a cGMP inspection carried out by the US FDA at its Tarapur facility. The inspection closed with one observation, a procedural deficiency. The inspection at the site was conducted between 27th and 31st August 2018 by three FDA investigators.
 
-
 
 
16th May 2017
 

Lupin completes major expansion of U.S. manufacturing facility

 
A U.S. generics manufacturing site that India’s Lupin picked up in its 2015 buyout of GAVIS Pharmaceuticals has now been significantly expanded as the drugmaker continues to make a push into the U.S. market.
 
- - -
 
Printed: 10-Apr-2026 at 09:23:05 hrs
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com